schliessen

Filtern

 

Bibliotheken

MR-spectroscopy guided target delineation for high-grade gliomas

Purpose: Functional/metabolic information provided by MR-spectroscopy (MRSI) suggests MRI may not be a reliable indicator of active and microscopic disease in malignant brain tumors. We assessed the impact MRSI might have on the target volumes used for radiation therapy treatment planning for high-g... Full description

Journal Title: International Journal of Radiation Oncology Biology, Physics, 2001, Vol.50(4), pp.915-928
Main Author: Pirzkall, Andrea
Other Authors: Mcknight, Tracy R , Graves, Edward E , Carol, Mark P , Sneed, Penny K , Wara, William W , Nelson, Sarah J , Verhey, Lynn J , Larson, David A
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0360-3016 ; E-ISSN: 1879-355X ; DOI: 10.1016/S0360-3016(01)01548-6
Link: https://www.sciencedirect.com/science/article/pii/S0360301601015486
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_S0360_3016_01_01548_6
title: MR-spectroscopy guided target delineation for high-grade gliomas
format: Article
creator:
  • Pirzkall, Andrea
  • Mcknight, Tracy R
  • Graves, Edward E
  • Carol, Mark P
  • Sneed, Penny K
  • Wara, William W
  • Nelson, Sarah J
  • Verhey, Lynn J
  • Larson, David A
subjects:
  • Brain Tumor
  • Astrocytoma
  • High-Grade Glioma
  • Magnetic Resonance Imaging (Mri)
  • Mr-Spectroscopy (Mrsi)
  • Intensity-Modulated Radiation Therapy (Imrt)
  • Medicine
ispartof: International Journal of Radiation Oncology, Biology, Physics, 2001, Vol.50(4), pp.915-928
description: Purpose: Functional/metabolic information provided by MR-spectroscopy (MRSI) suggests MRI may not be a reliable indicator of active and microscopic disease in malignant brain tumors. We assessed the impact MRSI might have on the target volumes used for radiation therapy treatment planning for high-grade gliomas. Methods and Materials: Thirty-four patients (22 Grade III; 12 Grade IV astrocytomas) were evaluated; each had undergone MRI and MRSI studies before surgery. MRI data sets were contoured for T1 region of contrast enhancement (T1), region of necrosis, and T2 region of hyperintensity (T2). The three-dimensional MRSI peak parameters for choline (Cho) and N -acetylaspartate (NAA), acquired by a multivoxel technique, were categorized based on an abnormality index (AI), a quantitative assessment of tissue metabolite levels. The AI data were aligned to the MRI and displayed as three-dimensional contours. AI vs. T conjoint and disjoint volumes were compared. Results: For both grades, although T2 estimated the region at risk of microscopic disease as being as much as 50% greater than by MRSI, metabolically active tumor still extended outside the T2 region in 88% of patients by as many as 28 mm. In addition, T1 suggested a lesser volume and different location of active disease compared to MRSI. Conclusion: The use of MRSI to define target volumes for RT treatment planning would increase, and change the location of, the volume receiving a boost dose as well as reduce the volume receiving a standard dose. Incorporation of MRSI into the treatment-planning process may have the potential to improve control while reducing complications.
language: eng
source:
identifier: ISSN: 0360-3016 ; E-ISSN: 1879-355X ; DOI: 10.1016/S0360-3016(01)01548-6
fulltext: fulltext
issn:
  • 0360-3016
  • 03603016
  • 1879-355X
  • 1879355X
url: Link


@attributes
ID1802480013
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_S0360_3016_01_01548_6
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_S0360_3016_01_01548_6
sourcesystemPC
dbid
0--K
1.FO
21B1
31P~
41RT
5457
64G.
77-5
8AAEDT
9AAQFI
10ACIUM
11ADPAM
12AEVXI
13AFTJW
14AGRDE
15AHHHB
16AITUG
17AJUYK
18ALXNB
19BELOY
20FDB
21FGOYB
22FIRID
23GBLVA
24HED
25HMO
26J1W
27KOM
28OC~
29OO-
30R2-
31RPZ
32SDG
33SEL
34SES
35SEW
36SSZ
37UV1
38XH2
39Z5R
pqid70992777
display
typearticle
titleMR-spectroscopy guided target delineation for high-grade gliomas
creatorPirzkall, Andrea ; Mcknight, Tracy R ; Graves, Edward E ; Carol, Mark P ; Sneed, Penny K ; Wara, William W ; Nelson, Sarah J ; Verhey, Lynn J ; Larson, David A
ispartofInternational Journal of Radiation Oncology, Biology, Physics, 2001, Vol.50(4), pp.915-928
identifier
subjectBrain Tumor ; Astrocytoma ; High-Grade Glioma ; Magnetic Resonance Imaging (Mri) ; Mr-Spectroscopy (Mrsi) ; Intensity-Modulated Radiation Therapy (Imrt) ; Medicine
languageeng
source
descriptionPurpose: Functional/metabolic information provided by MR-spectroscopy (MRSI) suggests MRI may not be a reliable indicator of active and microscopic disease in malignant brain tumors. We assessed the impact MRSI might have on the target volumes used for radiation therapy treatment planning for high-grade gliomas. Methods and Materials: Thirty-four patients (22 Grade III; 12 Grade IV astrocytomas) were evaluated; each had undergone MRI and MRSI studies before surgery. MRI data sets were contoured for T1 region of contrast enhancement (T1), region of necrosis, and T2 region of hyperintensity (T2). The three-dimensional MRSI peak parameters for choline (Cho) and N -acetylaspartate (NAA), acquired by a multivoxel technique, were categorized based on an abnormality index (AI), a quantitative assessment of tissue metabolite levels. The AI data were aligned to the MRI and displayed as three-dimensional contours. AI vs. T conjoint and disjoint volumes were compared. Results: For both grades, although T2 estimated the region at risk of microscopic disease as being as much as 50% greater than by MRSI, metabolically active tumor still extended outside the T2 region in 88% of patients by as many as 28 mm. In addition, T1 suggested a lesser volume and different location of active disease compared to MRSI. Conclusion: The use of MRSI to define target volumes for RT treatment planning would increase, and change the location of, the volume receiving a boost dose as well as reduce the volume receiving a standard dose. Incorporation of MRSI into the treatment-planning process may have the potential to improve control while reducing complications.
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301601015486$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Pirzkall, Andrea
1Mcknight, Tracy R
2Graves, Edward E
3Carol, Mark P
4Sneed, Penny K
5Wara, William W
6Nelson, Sarah J
7Verhey, Lynn J
8Larson, David A
titleMR-spectroscopy guided target delineation for high-grade gliomas
subject
0Brain Tumor
1Astrocytoma
2High-Grade Glioma
3Magnetic Resonance Imaging (Mri)
4Mr-Spectroscopy (Mrsi)
5Intensity-Modulated Radiation Therapy (Imrt)
6Medicine
general
0English
1Elsevier Inc
210.1016/S0360-3016(01)01548-6
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_S0360_3016_01_01548_6
issn
00360-3016
103603016
21879-355X
31879355X
rsrctypearticle
creationdate2001
addtitleInternational Journal of Radiation Oncology, Biology, Physics
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1.FO
21B1
31P~
41RT
5457
64G.
77-5
8AAEDT
9AAQFI
10ACIUM
11ADPAM
12AEVXI
13AFTJW
14AGRDE
15AHHHB
16AITUG
17AJUYK
18ALXNB
19BELOY
20FDB
21FGOYB
22FIRID
23GBLVA
24HED
25HMO
26J1W
27KOM
28OC~
29OO-
30R2-
31RPZ
32SDG
33SEL
34SES
35SEW
36SSZ
37UV1
38XH2
39Z5R
startdate20010101
enddate20011231
lsr40International Journal of Radiation Oncology, Biology, Physics, 2001, Vol.50 (4), pp.915-928
doi10.1016/S0360-3016(01)01548-6
citationpf 915 pt 928 vol 50 issue 4
lsr30VSR-Enriched:[description, pqid]
sort
titleMR-spectroscopy guided target delineation for high-grade gliomas
authorPirzkall, Andrea ; Mcknight, Tracy R ; Graves, Edward E ; Carol, Mark P ; Sneed, Penny K ; Wara, William W ; Nelson, Sarah J ; Verhey, Lynn J ; Larson, David A
creationdate20010000
lso0120010000
facets
frbrgroupid3213535383112877655
frbrtype5
newrecords20190904
languageeng
topic
0Brain Tumor
1Astrocytoma
2High-Grade Glioma
3Magnetic Resonance Imaging (Mri)
4Mr-Spectroscopy (Mrsi)
5Intensity-Modulated Radiation Therapy (Imrt)
6Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Pirzkall, Andrea
1Mcknight, Tracy R
2Graves, Edward E
3Carol, Mark P
4Sneed, Penny K
5Wara, William W
6Nelson, Sarah J
7Verhey, Lynn J
8Larson, David A
jtitleInternational Journal of Radiation Oncology, Biology, Physics
creationdate2001
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Pirzkall
1Mcknight
2Graves
3Carol
4Sneed
5Wara
6Nelson
7Verhey
8Larson
aufirst
0Andrea
1Tracy R
2Edward E
3Mark P
4Penny K
5William W
6Sarah J
7Lynn J
8David A
auinitA
auinit1A
au
0Pirzkall, Andrea
1Mcknight, Tracy R
2Graves, Edward E
3Carol, Mark P
4Sneed, Penny K
5Wara, William W
6Nelson, Sarah J
7Verhey, Lynn J
8Larson, David A
atitleMR-spectroscopy guided target delineation for high-grade gliomas
jtitleInternational Journal of Radiation Oncology, Biology, Physics
date2001
risdate2001
volume50
issue4
spage915
epage928
pages915-928
issn0360-3016
eissn1879-355X
formatjournal
genrearticle
ristypeJOUR
pubElsevier Inc
doi10.1016/S0360-3016(01)01548-6
lad01International Journal of Radiation Oncology, Biology, Physics